Deucravacitinib
- Generic Name
- Deucravacitinib
- Brand Names
- Sotyktu
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O3
- CAS Number
- 1609392-27-9
- Unique Ingredient Identifier
- N0A21N6RAU
- Background
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selectivity towards TYK2 may lead to an improved...
- Indication
Deucravacitinib is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is not recommended for use in combination with other potent immunosuppressants.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Vitiligo Treatment by Targeting TYK2 Mediated Responses
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 128
- Registration Number
- NCT06327321
- Locations
- 🇫🇷
APHP, Henri Mondor, Paris, Creteil, France
🇫🇷CHU de Bordeaux, Bordeaux, Talence, France
🇫🇷CHU de Nice - Hôpital de l'Archet, Nice, Alpes-Maritimes, France
Combination of Sotyktu and Enstilar for Plaque Psoriasis
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Psoriasis Treatment Center of Central New Jersey
- Target Recruit Count
- 30
- Registration Number
- NCT06329258
- Locations
- 🇺🇸
Schweiger Derm Group, East Windsor, New Jersey, United States
TYK2 Inhibition in Paradoxical Psoriasis
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Prof Curdin Conrad
- Target Recruit Count
- 26
- Registration Number
- NCT06281106
- Locations
- 🇨🇭
Centre hospitalier universitaire vaudois (CHUV), Lausanne, VD, Switzerland
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 505
- Registration Number
- NCT06258668
- Locations
- 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 731
- Registration Number
- NCT06220604
- Locations
- 🇩🇪
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
🇵🇱WroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
🇺🇸Essential Medical Research, Tulsa, Oklahoma, United States
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 774
- Registration Number
- NCT06143878
- Locations
- 🇧🇷
Fundacao do ABC Centro Universitario FMABC, Santo Andre, Brazil
🇵🇱WroMedica I.Bielicka, A.Strzalkowska s.c., Wrocław, Poland
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 10
- Registration Number
- NCT06136403
- Locations
- 🇫🇷
CHU de Nice, Nice, Chu de Nice, France
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 550
- Registration Number
- NCT06104644
- Locations
- 🇩🇪
Dermatologische Spezial- und Schwerpunktpraxis Selters, Selters, Rhineland-Palatinate, Germany
🇩🇪Company for Medical Study & Service Selters, Selters, Germany
A Study of Deucravacitinib to Treat LPP and FFA
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT06091956
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 360
- Registration Number
- NCT06042920
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai-Department of Dermatology, New York, New York, United States
🇺🇸Apex Clinical Research Center, LLC, Mayfield Heights, Ohio, United States
🇨🇦Canadian Dermatology Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.